J&J Resumes all Clinical Trial of its COVID-19 Vaccine in the EU

Share this

J&J Resumes all Clinical Trial of its COVID-19 Vaccine in the EU


  • J&J has resumed recruitment- enrolment- and vaccination in all studies of its COVID-19 vaccine across the EU- after a temporary pause. Trials in the US- South Africa- and some Latin American countries are already ongoing
  • Clinical trials to be resumed are the P-IIa studies in Germany- the Netherlands- and Spain and P-I/IIa study in Belgium
  • The company is preparing for the initiation of a second P-III study of the COVID-19 vaccine candidate. The trial will evaluate a 2-dose regimen and is anticipated to start later this month across the EU. The study follows positive interim results of the P-I/IIa study- showing the safety profile and immunogenicity of the COVID-19 vaccine was supportive of further development

 ­ Ref: Janssen | Image: Law.com

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions